Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WORX vs SOPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

WORX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 3–5 Matrix Metrics)

WORX Overall Winner 6-Pillar Tally: WORX 4 – 2 SOPH Matrix Metrics: WORX 3 – 5 SOPH

As of Nov 16, 2026, SC WORX Corp (WORX) is the stronger overall head-to-head candidate over SOPHiA GENETICS SA (SOPH) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas SOPH carries 49.8/100 (HOLD) at $7.44 (N/M Forward P/E, -81.0% operating margin).

  • Composite vs. Pillar Nuance: While SOPH currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. WORX 34.1/100 SELL), WORX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-20.1% vs. -81.0% operating margin) and revenue trajectory (+3.4% vs. +24.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WORX vs SOPH
WORX NASDAQ Head-to-Head Winner
SC WORX Corp
Services-Computer Processing & Data Preparation
$1.15
-6.5% 1D
Market Cap $1.7M
TTM Revenue $2.9M
Forward P/E N/M
Beta / 30D Vol 23.01β · 208% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 15.0 Fund 31.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 71
RSI-14: 71.4 · SMA20: $0.24 · SMA50: $0.24
SOPH NASDAQ
SOPHiA GENETICS SA Ordinary Shares
Services-Computer Processing & Data Preparation
$7.44
-9.38% 1D
Market Cap $703.3M
TTM Revenue $91M
Forward P/E N/M
Beta / 30D Vol 1.28β · 78% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 23.0 Fund 48.0 Flow 60.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.1 · SMA20: $7.43 · SMA50: $7.64

6-Pillar Scorecard Institutional Category Breakdown (WORX 4 – 2 SOPH)

Columns: Metric · WORX · SOPH
1. Valuation Multiples WORX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x 7.4x
2. Growth & Scale SOPH
Revenue Growth (YoY) +3.4% +24.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.9M $91M
Market Cap $1.7M $703.3M
3. Profitability & Quality WORX
Gross Margin 44.7% 66.4%
Operating Margin -20.1% -81.0%
Net Profit Margin -80.5% -89.2%
Return on Equity (ROE) -38.1% -125.7%
4. Balance Sheet & Cash Flow WORX
Cash Generation (TTM) -$914,262 -$51M
Cash Flow Margin -31.2% -55.8%
Net Cash / Leverage $77.66 Book/Sh · -38.1% ROE $33M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SOPH
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 68.1% (38th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat WORX
OpEx & R&D Intensity 64.8% of Rev ($1.9M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WORX (3) vs SOPH (5)
Institutional Metric WORX SOPH Criterion Row Edge
Market Capitalization
Scale
$1.7M $703.3M Larger Scale SOPH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+3.4% +24.7% Higher Growth SOPH
Operating Margin (TTM)
Profitability
-20.1% -81.0% Higher Margin WORX
Net Profit Margin
Profitability
-80.5% -89.2% Higher Margin WORX
Return on Equity (ROE)
Capital Efficiency
-38.1% -125.7% Higher ROE WORX
52-Week Range Position
Momentum
17% ($0–$6) 70% ($4–$9) Stronger Trend SOPH
Beta / 30D Volatility
Risk Regime
23.01β · 208% Vol 1.28β · 78% Vol Lower Realized Risk SOPH
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 49.8 / 100 (HOLD) Higher Composite SOPH
Trailing 12M Revenue (USD)
Operating Scale
$2.9M $91M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.7% 66.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$914,262 ($77.66 Book/Sh · -38.1% ROE) -$51M ($33M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SOPH +27.22 pp
WORX: -16.67% · SOPH: +10.55%
3M Horizon WORX +166.64 pp
WORX: +228.38% · SOPH: +61.74%
6M Horizon WORX +241.81 pp
WORX: +327.35% · SOPH: +85.54%
1Y Horizon WORX +192.92 pp
WORX: +262.78% · SOPH: +69.86%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period WORX Revenue SOPH Revenue WORX Op. Margin SOPH Op. Margin Margin Leader
Q3 '25 $0M $80M -19.7% -91.8% WORX
Q4 '25 $0M $90M -25.0% -85.3% WORX
Q1 '26 $0M $90M -18.2% -79.7% WORX
Q2 '26 $0M $90M -17.1% -86.0% WORX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WORX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WORX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SOPH CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 68.1%
IV Percentile 38th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SOPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WORX Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.7M market capitalization and -20.1% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($1.9M)
90D Engineering Disclosures 0 Published
SOPH Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $703.3M market capitalization and -81.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WORX vs SOPH Key Questions & Quantitative Answers

As of Nov 16, 2026, SC WORX Corp (WORX) is the stronger overall head-to-head candidate over SOPHiA GENETICS SA (SOPH) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). WORX carries a Unified Composite Score of 34.1/100 (SELL) at $1.15 (N/M Forward P/E, -20.1% operating margin), whereas SOPH carries 49.8/100 (HOLD) at $7.44 (N/M Forward P/E, -81.0% operating margin). Composite vs. Pillar Nuance: While SOPH currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. WORX 34.1/100 SELL), WORX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-20.1% vs. -81.0% operating margin) and revenue trajectory (+3.4% vs. +24.7% YoY).

SOPH leads the Growth & Scale pillar: WORX posts +3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (44.7% gross margin, -20.1% operating margin), compared with SOPH at +24.7% YoY revenue growth and +0.0% YoY earnings growth on $91M TTM revenue (66.4% gross margin, -81.0% operating margin). Across the 4-period historical trajectory (Q3 '25 to Q2 '26), WORX cumulative revenue shifted N/A while SOPH shifted +12.5%. In operating R&D and SG&A reinvestment, WORX deploys 64.8% of Rev ($1.9M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SOPH.

WORX screens cheaper on headline valuation multiples. WORX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-31.2% FCF margin), whereas SOPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-55.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WORX (-38.1% ROE) versus SOPH (-125.7% ROE) capital efficiency.

In options market volatility and institutional positioning, WORX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (23.01β · 208% Vol realized risk). By comparison, SOPH carries 68.1% implied volatility (38th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.